Toleranzia Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Toleranzia
Access all reports
Toleranzia AB is a biotechnology company specializing in the development of protein-based drugs for the treatment of autoimmune diseases. The company leverages its proprietary platform to create therapeutic proteins aimed at inducing immune tolerance in patients, addressing the underlying causes of autoimmune conditions rather than merely alleviating symptoms. Toleranzia focuses on diseases with significant unmet medical needs, striving to provide innovative treatments that can improve patients' quality of life. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
TOL
Country
🇸🇪 Sweden